Home BP Monitoring Cost Effective for Insurers
Estimated first-year savings ranged from $33 to $166 per member.
Topics
Weight Loss Linked to Hot Flash Reduction
A behavioral intervention was effective in helping overweight or obese menopausal women lose weight and reduce hot flashes.
CV Health Associated With Neighborhood
Favorable food stores and physical activity resources in neighborhoods were linked to ideal cardiovascular health.
Whey Protein May Lower Glucose in Type 2 Diabetes
Whey pre-load is associated with a reduction in glucose levels as well as improved early insulin response and GLP-1 levels.
FDA to Review New Drug Application (NDA) for Touejo
The FDA has accepted for review its New Drug Application (NDA) for Toujeo (insulin glargine [rDNA origin]) injection.
Identifying Men Who Benefit from Drug Treatment for Fracture Prevention
WHO criteria better than National Osteoporosis Foundation criteria for identifying men who would benefit from drug treatment.
Three Forms of Generic Testosterone Gel Launched
Upsher-Smith announced the launch of Testosterone Gel 1%, the generic version of Vogelxo gel, in 3 different configurations.
Afrezza Receives FDA Approval
The FDA announced the approval of Afrezza (insulin human; MannKind) Inhalation Powder for type 1 and type 2 diabetes.
FDA Finds No Increased CV Risk With Olmesartan in Diabetes Patients
The FDA has found no clear evidence of increased cardiovascular risks associated with olmesartan medoxomil in patients with diabetes.
FDA Requires New Warning for Testosterone Products
The FDA now requires a general warning in the drug labeling of all approved testosterone products regarding the risk of venous blood clots.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Androgen and Reproductive Disorders
